<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33782012</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>18</Day></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e02576-20</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.02576-20</ELocationID><Abstract><AbstractText>A high-throughput screen of a Roche internal chemical library based on inhibition of the respiratory syncytial virus (RSV)-induced cytopathic effect (CPE) on HEp-2 cells was performed to identify RSV inhibitors. Over 2,000 hits were identified and confirmed to be efficacious against RSV infection <i>in vitro</i> Here, we report the discovery of a triazole-oxadiazole derivative, designated triazole-1, as an RSV replication inhibitor, and we characterize its mechanism of action. Triazole-1 inhibited the replication of both RSV A and B subtypes with 50% inhibitory concentration (IC<sub>50</sub>) values of approximately 1&#x2009;&#x3bc;M, but it was not effective against other viruses, including influenza virus A, human enterovirus 71 (EV71), and vaccinia virus. Triazole-1 was shown to inhibit RSV replication when added at up to 8&#x2009;h after viral entry, suggesting that it inhibits RSV after viral entry. In a minigenome reporter assay in which RSV transcription regulatory sequences flanking a luciferase gene were cotransfected with RSV N/P/L/M2-1 genes into HEp-2 cells, triazole-1 demonstrated specific and dose-dependent RSV transcription inhibitory effects. Consistent with these findings, deep sequencing of the genomes of triazole-1-resistant mutants revealed a single point mutation (A to G) at nucleotide 13546 of the RSV genome, leading to a T-to-A change at amino acid position 1684 of the L protein, which is the RSV RNA polymerase for both viral transcription and replication. The effect of triazole-1 on minigenome transcription, which was mediated by the L protein containing the T1684A mutation, was significantly reduced, suggesting that the T1684A mutation alone conferred viral resistance to triazole-1.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Wang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Li</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-9580-2476</Identifier><AffiliationInfo><Affiliation>Infectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China vlwang00@163.com goodlucksept2016@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhu</LastName><ForeName>Qihui</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Infectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Kunlun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Infectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yaling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Infectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Baocun</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Infectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Infectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Guang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Infectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Chungen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medicinal Chemistry, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yun</LastName><ForeName>Hongying</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medicinal Chemistry, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Meifang</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Lead Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Lead Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Infectious Disease Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Shanghai, Shanghai, China vlwang00@163.com goodlucksept2016@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018357" MajorTopicYN="Y">Respiratory Syncytial Virus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018113" MajorTopicYN="Y">Respiratory Syncytial Virus, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014616" MajorTopicYN="N">Vaccinia virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">inhibitor</Keyword><Keyword MajorTopicYN="N">replication</Keyword><Keyword MajorTopicYN="N">respiratory syncytial virus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>7</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33782012</ArticleId><ArticleId IdType="pmc">PMC8316115</ArticleId><ArticleId IdType="doi">10.1128/AAC.02576-20</ArticleId><ArticleId IdType="pii">AAC.02576-20</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, Cohen HJ. 1986. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 315:77&#x2013;81. 10.1056/NEJM198607103150201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198607103150201</ArticleId><ArticleId IdType="pubmed">3724802</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. 2009. The burden of respiratory syncytial virus infection in youngchildren. N Engl J Med 360:588&#x2013;598. 10.1056/NEJMoa0804877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0804877</ArticleId><ArticleId IdType="pmc">PMC4829966</ArticleId><ArticleId IdType="pubmed">19196675</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352:1749&#x2013;1759. 10.1056/NEJMoa043951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa043951</ArticleId><ArticleId IdType="pubmed">15858184</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins PL, Graham BS. 2008. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 82:2040&#x2013;2055. 10.1128/JVI.01625-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01625-07</ArticleId><ArticleId IdType="pmc">PMC2258918</ArticleId><ArticleId IdType="pubmed">17928346</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham BS. 2011. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 239:149&#x2013;166. 10.1111/j.1600-065X.2010.00972.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2010.00972.x</ArticleId><ArticleId IdType="pmc">PMC3023887</ArticleId><ArticleId IdType="pubmed">21198670</ArticleId></ArticleIdList></Reference><Reference><Citation>Anonymous. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102:531&#x2013;537. 10.1542/peds.102.3.531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.102.3.531</ArticleId><ArticleId IdType="pubmed">9738173</ArticleId></ArticleIdList></Reference><Reference><Citation>de Fontbrune FS, Robin M, Porcher R, Scieux C, de Latour RP, Ferry C, Rocha V, Boudjedir K, Devergie A, Bergeron A, Gluckman E, Azoulay E, Lapalu J, Soci&#xe9; G, Ribaud P. 2007. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 45:1019&#x2013;1024. 10.1086/521912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/521912</ArticleId><ArticleId IdType="pubmed">17879919</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventre K, Randolph AG. 2007. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev (1):CD000181. 10.1002/14651858.CD000181.pub3:Cd000181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD000181.pub3:Cd000181</ArticleId><ArticleId IdType="pubmed">17253446</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding WD, Mitsner B, Krishnamurthy G, Aulabaugh A, Hess CD, Zaccardi J, Cutler M, Feld B, Gazumyan A, Raifeld Y, Nikitenko A, Lang SA, Gluzman Y, O&#x2019;Hara B, Ellestad GA. 1998. Novel and specific respiratory syncytial virus inhibitors that target virus fusion. J Med Chem 41:2671&#x2013;2675. 10.1021/jm980239e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm980239e</ArticleId><ArticleId IdType="pubmed">9667956</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyde PR, Moore-Poveda DK, O'Hara B, Ding WD, Mitsner B, Gilbert BE. 1998. CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats. Antiviral Res 38:31&#x2013;42. 10.1016/S0166-3542(98)00002-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-3542(98)00002-3</ArticleId><ArticleId IdType="pubmed">9614002</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntley CC, Weiss WJ, Gazumyan A, Buklan A, Feld B, Hu W, Jones TR, Murphy T, Nikitenko AA, O&#x2019;Hara B, Prince G, Quartuccio S, Raifeld YE, Wyde P, O&#x2019;Connell JF. 2002. RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob Agents Chemother 46:841&#x2013;847. 10.1128/aac.46.3.841-847.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.46.3.841-847.2002</ArticleId><ArticleId IdType="pmc">PMC127488</ArticleId><ArticleId IdType="pubmed">11850270</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas JL, Panis ML, Ho E, Lin KY, Krawczyk SH, Grant DM, Cai R, Swaminathan S, Cihlar T. 2003. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. JVI 77:5054&#x2013;5064. 10.1128/JVI.77.9.5054-5064.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.9.5054-5064.2003</ArticleId><ArticleId IdType="pmc">PMC153948</ArticleId><ArticleId IdType="pubmed">12692208</ArticleId></ArticleIdList></Reference><Reference><Citation>Cianci C, Yu KL, Combrink K, Sin N, Pearce B, Wang A, Civiello R, Voss S, Luo G, Kadow K, Genovesi EV, Venables B, Gulgeze H, Trehan A, James J, Lamb L, Medina I, Roach J, Yang Z, Zadjura L, Colonno R, Clark J, Meanwell N, Krystal M. 2004. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother 48:413&#x2013;422. 10.1128/aac.48.2.413-422.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.48.2.413-422.2004</ArticleId><ArticleId IdType="pmc">PMC321540</ArticleId><ArticleId IdType="pubmed">14742189</ArticleId></ArticleIdList></Reference><Reference><Citation>Cianci C, Meanwell N, Krystal M. 2005. Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. J Antimicrob Chemother 55:289&#x2013;292. 10.1093/jac/dkh558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkh558</ArticleId><ArticleId IdType="pubmed">15681582</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonfanti JF, Meyer C, Doublet F, Fortin J, Muller P, Queguiner L, Gevers T, Janssens P, Szel H, Willebrords R, Timmerman P, Wuyts K, van Remoortere P, Janssens F, Wigerinck P, Andries K. 2008. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Med Chem 51:875&#x2013;896. 10.1021/jm701284j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm701284j</ArticleId><ArticleId IdType="pubmed">18254606</ArticleId></ArticleIdList></Reference><Reference><Citation>Devincenzo J, Fathi H, Mcclure M, Westland C, Chanda S, Lambkin-Williams R, Smith P, Harrison L, Symons J, Scaglioni-Weinlich C, Zhang Q, Nieforth K, Beigelman L, Blatt L, Fry J. 2014. Treatment with oral ALS-008176, a nucleoside analog, rapidly reduces RSV viral load and clinical disease severity in a healthy volunteer challenge study. Open Forum Infect Dis 1:S66. 10.1093/ofid/ofu083.01.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofu083.01</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackman RL, Sangi M, Sperandio D, Parrish JP, Eisenberg E, Perron M, Hui H, Zhang L, Siegel D, Yang H, Saunders O, Boojamra C, Lee G, Samuel D, Babaoglu K, Carey A, Gilbert BE, Piedra PA, Strickley R, Iwata Q, Hayes J, Stray K, Kinkade A, Theodore D, Jordan R, Desai M, Cihlar T. 2015. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem 58:1630&#x2013;1643. 10.1021/jm5017768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm5017768</ArticleId><ArticleId IdType="pubmed">25574686</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z, Pan Y, Jiang S, Lu L. 2013. Respiratory syncytial virus entry inhibitors targeting the F protein. Viruses 5:211&#x2013;225. 10.3390/v5010211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v5010211</ArticleId><ArticleId IdType="pmc">PMC3564118</ArticleId><ArticleId IdType="pubmed">23325327</ArticleId></ArticleIdList></Reference><Reference><Citation>Marty FM, Chemaly RF, Mullane KM, Lee DG, Hirsch HH, Small CB, Bergeron A, Shoham S, Ljungman P, Waghmare A, Blanchard E, Kim YJ, McKevitt M, Porter DP, Jordan R, Guo Y, German P, Boeckh M, Watkins TR, Chien JW, Dadwal SS. 2019. A phase 2b, randomized, double-blind, placebo-controlled multicenter study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus (RSV) infection of the lower respiratory tract. Clin Infect Dis 71:2787&#x2013;2795. 10.1093/cid/ciz1167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz1167</ArticleId><ArticleId IdType="pmc">PMC7108198</ArticleId><ArticleId IdType="pubmed">31915807</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins PL, Hill MG, Cristina J, Grosfeld H. 1996. Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus. Proc Natl Acad Sci U S A 93:81&#x2013;85. 10.1073/pnas.93.1.81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.1.81</ArticleId><ArticleId IdType="pmc">PMC40182</ArticleId><ArticleId IdType="pubmed">8552680</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Barreno B, Delgado T, Melero JA. 1996. Identification of protein regions involved in the interaction of human respiratory syncytial virus phosphoprotein and nucleoprotein: significance for nucleocapsid assembly and formation of cytoplasmic inclusions. J Virol 70:801&#x2013;808. 10.1128/JVI.70.2.801-808.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.70.2.801-808.1996</ArticleId><ArticleId IdType="pmc">PMC189882</ArticleId><ArticleId IdType="pubmed">8551618</ArticleId></ArticleIdList></Reference><Reference><Citation>Slack MS, Easton AJ. 1998. Characterization of the interaction of the human respiratory syncytial virus phosphoprotein and nucleocapsid protein using the two-hybrid system. Virus Res 55:167&#x2013;176. 10.1016/s0168-1702(98)00042-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0168-1702(98)00042-2</ArticleId><ArticleId IdType="pubmed">9725669</ArticleId></ArticleIdList></Reference><Reference><Citation>Khattar SK, Yunus AS, Samal SK. 2001. Mapping the domains on the phosphoprotein of bovine respiratory syncytial virus required for N-P and P-L interactions using a minigenome system. J Gen Virol 82:775&#x2013;779. 10.1099/0022-1317-82-4-775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-82-4-775</ArticleId><ArticleId IdType="pubmed">11257181</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason SW, Aberg E, Lawetz C, DeLong R, Whitehead P, Liuzzi M. 2003. Interaction between human respiratory syncytial virus (RSV) M2-1 and P proteins is required for reconstitution of M2-1-dependent RSV minigenome activity. J Virol 77:10670&#x2013;10676. 10.1128/jvi.77.19.10670-10676.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.77.19.10670-10676.2003</ArticleId><ArticleId IdType="pmc">PMC228475</ArticleId><ArticleId IdType="pubmed">12970453</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins PL, Fearns R, Graham BS. 2013. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol 372:3&#x2013;38. 10.1007/978-3-642-38919-1_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-38919-1_1</ArticleId><ArticleId IdType="pmc">PMC4794264</ArticleId><ArticleId IdType="pubmed">24362682</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman J, Abbott E, Alber DG, Baxter RC, Bithell SK, Henderson EA, Carter MC, Chambers P, Chubb A, Cockerill GS, Collins PL, Dowdell VC, Keegan SJ, Kelsey RD, Lockyer MJ, Luongo C, Najarro P, Pickles RJ, Simmonds M, Taylor D, Tyms S, Wilson LJ, Powell KL. 2007. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother 51:3346&#x2013;3353. 10.1128/AAC.00211-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00211-07</ArticleId><ArticleId IdType="pmc">PMC2043207</ArticleId><ArticleId IdType="pubmed">17576833</ArticleId></ArticleIdList></Reference><Reference><Citation>Challa S, Scott AD, Yuzhakov O, Zhou Y, Tiong-Yip CL, Gao N, Thresher J, Yu Q. 2015. Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother 59:1080&#x2013;1087. 10.1128/AAC.04119-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.04119-14</ArticleId><ArticleId IdType="pmc">PMC4335855</ArticleId><ArticleId IdType="pubmed">25451060</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman J, Cockerill S. 2011. Discovery and development of RSV604, p 367&#x2013;382. In Kazmierski WM (ed), Antiviral drugs: from basic discovery through clinical trials. John Wiley &amp; Sons, Hoboken, NJ.</Citation></Reference><Reference><Citation>Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. 2019. Advances in respiratory virus therapeutics&#x2014;a meeting report from the 6th isirv Antiviral Group conference. Antiviral Res 167:45&#x2013;67. 10.1016/j.antiviral.2019.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.04.006</ArticleId><ArticleId IdType="pmc">PMC7132446</ArticleId><ArticleId IdType="pubmed">30974127</ArticleId></ArticleIdList></Reference><Reference><Citation>Roymans D, Koul A. 2011. Treatment of respiratory syncytial virus infection: past, present and future. InHuman respiratory syncytial virus infection. IntechOpen, London, United Kingdom.</Citation></Reference><Reference><Citation>Stec DS, HillMG, 3rd, Collins PL. 1991. Sequence analysis of the polymerase L gene of human respiratory syncytial virus and predicted phylogeny of nonsegmented negative-strand viruses. Virology 183:273&#x2013;287. 10.1016/0042-6822(91)90140-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(91)90140-7</ArticleId><ArticleId IdType="pubmed">2053282</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Deval J, Hong J, Dyatkina N, Prhavc M, Taylor J, Fung A, Jin Z, Stevens SK, Serebryany V, Liu J, Zhang Q, Tam Y, Chanda SM, Smith DB, Symons JA, Blatt LM, Beigelman L. 2015. Discovery of 4&#x2032;-chloromethyl-2&#x2032;-deoxy-3&#x2032;,5&#x2032;-di-O-isobutyryl-2&#x2032;-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem 58:1862&#x2013;1878. 10.1021/jm5017279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm5017279</ArticleId><ArticleId IdType="pubmed">25667954</ArticleId></ArticleIdList></Reference><Reference><Citation>Laganas VA, Dunn EF, McLaughlin RE, Tiong-Yip CL, Yuzhakov O, Isabella VM, Hill P, Yu Q. 2015. Characterization of novel respiratory syncytial virus inhibitors identified by high throughput screen. Antiviral Res 115:71&#x2013;74. 10.1016/j.antiviral.2014.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.12.012</ArticleId><ArticleId IdType="pubmed">25542974</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke MO, Mackman R, Byun D, Hui H, Barauskas O, Birkus G, Chun BK, Doerffler E, Feng J, Karki K, Lee G, Perron M, Siegel D, Swaminathan S, Lee W. 2015. Discovery of &#x3b2;-d-2&#x2032;-deoxy-2&#x2032;-&#x3b1;-fluoro-4&#x2032;-&#x3b1;-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases. Bioorg Med Chem Lett 25:2484&#x2013;2487. 10.1016/j.bmcl.2015.04.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2015.04.073</ArticleId><ArticleId IdType="pubmed">25978965</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason SW, Lawetz C, Gaudette Y, D&#xf4; F, Scouten E, Lagac&#xe9; L, Simoneau B, Liuzzi M. 2004. Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor. Nucleic Acids Res 32:4758&#x2013;4767. 10.1093/nar/gkh809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkh809</ArticleId><ArticleId IdType="pmc">PMC519107</ArticleId><ArticleId IdType="pubmed">15356293</ArticleId></ArticleIdList></Reference><Reference><Citation>Liuzzi M, Mason SW, Cartier M, Lawetz C, McCollum RS, Dansereau N, Bolger G, Lapeyre N, Gaudette Y, Lagac&#xe9; L, Massariol MJ, D&#xf4; F, Whitehead P, Lamarre L, Scouten E, Bordeleau J, Landry S, Rancourt J, Fazal G, Simoneau B. 2005. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase. J Virol 79:13105&#x2013;13115. 10.1128/JVI.79.20.13105-13115.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.20.13105-13115.2005</ArticleId><ArticleId IdType="pmc">PMC1235819</ArticleId><ArticleId IdType="pubmed">16189012</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudo K, Miyazaki Y, Kojima N, Kobayashi M, Suzuki H, Shintani M, Shimizu Y. 2005. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Antiviral Res 65:125&#x2013;131. 10.1016/j.antiviral.2004.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2004.12.002</ArticleId><ArticleId IdType="pubmed">15708639</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiong-Yip CL, Aschenbrenner L, Johnson KD, McLaughlin RE, Fan J, Challa S, Xiong H, Yu Q. 2014. Characterization of a respiratory syncytial virus L protein inhibitor. Antimicrob Agents Chemother 58:3867&#x2013;3873. 10.1128/AAC.02540-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02540-14</ArticleId><ArticleId IdType="pmc">PMC4068518</ArticleId><ArticleId IdType="pubmed">24777090</ArticleId></ArticleIdList></Reference><Reference><Citation>Fordyce EAF, Brookes DW, Lise-Ciana C, Coates MS, Hunt SF, Ito K, King-Underwood J, Onions ST, Parra GF, Rapeport G, Sherbukhin V, Stockwell JA, Strong P, Thomas JC, Murray J. 2017. Discovery of novel benzothienoazepine derivatives as potent inhibitors of respiratory syncytial virus. Bioorg Med Chem Lett 27:2201&#x2013;2206. 10.1016/j.bmcl.2017.03.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2017.03.053</ArticleId><ArticleId IdType="pubmed">28372911</ArticleId></ArticleIdList></Reference><Reference><Citation>Coates M, Brookes D, Kim YI, Allen H, Fordyce EAF, Meals EA, Colley T, Ciana CL, Parra GF, Sherbukhin V, Stockwell JA, Thomas JC, Hunt SF, Anderson-Dring L, Onions ST, Cass L, Murray PJ, Ito K, Strong P, DeVincenzo JP, Rapeport G. 2017. Preclinical characterization of PC786, an inhaled small-molecule respiratory syncytial virus L protein polymerase inhibitor. Antimicrob Agents Chemother 61:e00737-17. 10.1128/AAC.00737-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00737-17</ArticleId><ArticleId IdType="pmc">PMC5571287</ArticleId><ArticleId IdType="pubmed">28652242</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookes DW, Coates M, Allen H, Daly L, Constant S, Huang S, Hows M, Davis A, Cass L, Ayrton J, Knowles I, Strong P, Rapeport G, Ito K. 2018. Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium. Br J Pharmacol 175:2520&#x2013;2534. 10.1111/bph.14221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14221</ArticleId><ArticleId IdType="pmc">PMC5980447</ArticleId><ArticleId IdType="pubmed">29579332</ArticleId></ArticleIdList></Reference><Reference><Citation>Roymans D, De Bondt HL, Arnoult E, Geluykens P, Gevers T, Van Ginderen M, Verheyen N, Kim H, Willebrords R, Bonfanti JF, Bruinzeel W, Cummings MD, van Vlijmen H, Andries K. 2010. Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci U S A 107:308&#x2013;313. 10.1073/pnas.0910108106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0910108106</ArticleId><ArticleId IdType="pmc">PMC2806771</ArticleId><ArticleId IdType="pubmed">19966279</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Liang C, Wang L, Wang B, Liu Y, Feng S, Wu JZ, Gao L, Feng L, Chen L, Guo T, Shen HC, Yun H. 2018. Discovery of benzoazepinequinoline (BAQ) derivatives as novel, potent, orally bioavailable respiratory syncytial virus fusion inhibitors. J Med Chem 61:10228&#x2013;10241. 10.1021/acs.jmedchem.8b01394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.8b01394</ArticleId><ArticleId IdType="pubmed">30339388</ArticleId></ArticleIdList></Reference><Reference><Citation>Grosfeld H, Hill MG, Collins PL. 1995. RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA. J Virol 69:5677&#x2013;5686. 10.1128/JVI.69.9.5677-5686.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.69.9.5677-5686.1995</ArticleId><ArticleId IdType="pmc">PMC189426</ArticleId><ArticleId IdType="pubmed">7637014</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonavia A, Franti M, Pusateri Keaney E, Kuhen K, Seepersaud M, Radetich B, Shao J, Honda A, Dewhurst J, Balabanis K, Monroe J, Wolff K, Osborne C, Lanieri L, Hoffmaster K, Amin J, Markovits J, Broome M, Skuba E, Cornella-Taracido I, Joberty G, Bouwmeester T, Hamann L, Tallarico JA, Tommasi R, Compton T, Bushell SM. 2011. Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV). Proc Natl Acad Sci U S A 108:6739&#x2013;6744. 10.1073/pnas.1017142108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1017142108</ArticleId><ArticleId IdType="pmc">PMC3084118</ArticleId><ArticleId IdType="pubmed">21502533</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirabelli C, Jaspers M, Boon M, Jorissen M, Koukni M, Bardiot D, Chaltin P, Marchand A, Neyts J, Jochmans D. 2018. Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium. JAntimicrob Chemother 73:1823&#x2013;1829. 10.1093/jac/dky089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dky089</ArticleId><ArticleId IdType="pmc">PMC6005027</ArticleId><ArticleId IdType="pubmed">29596680</ArticleId></ArticleIdList></Reference><Reference><Citation>Deval J, Hong J, Wang G, Taylor J, Smith LK, Fung A, Stevens SK, Liu H, Jin Z, Dyatkina N, Prhavc M, Stoycheva AD, Serebryany V, Liu J, Smith DB, Tam Y, Zhang Q, Moore ML, Fearns R, Chanda SM, Blatt LM, Symons JA, Beigelman L. 2015. Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2&#x2032;-fluoro-4&#x2032;-chloromethyl-cytidine triphosphate. PLoS Pathog 11:e1004995. 10.1371/journal.ppat.1004995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004995</ArticleId><ArticleId IdType="pmc">PMC4476725</ArticleId><ArticleId IdType="pubmed">26098424</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyle G. 2000. Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism? Drug Saf 23:467&#x2013;481. 10.2165/00002018-200023060-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200023060-00001</ArticleId><ArticleId IdType="pubmed">11144657</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong H, Foulk M, Aschenbrenner L, Fan J, Tiong-Yip CL, Johnson KD, Moustakas D, Fleming PR, Brown DG, Zhang M, Ferguson D, Wu D, Yu Q. 2013. Discovery of a potent respiratory syncytial virus RNA polymerase inhibitor. Bioorg Med Chem Lett 23:6789&#x2013;6793. 10.1016/j.bmcl.2013.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2013.10.018</ArticleId><ArticleId IdType="pubmed">24211022</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox RM, Toots M, Yoon JJ, Sourimant J, Ludeke B, Fearns R, Bourque E, Patti J, Lee E, Vernachio J, Plemper RK. 2018. Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex. J Biol Chem 293:16761&#x2013;16777. 10.1074/jbc.RA118.004862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.004862</ArticleId><ArticleId IdType="pmc">PMC6204889</ArticleId><ArticleId IdType="pubmed">30206124</ArticleId></ArticleIdList></Reference><Reference><Citation>Noton SL, Nagendra K, Dunn EF, Mawhorter ME, Yu Q, Fearns R. 2015. Respiratory syncytial virus inhibitor AZ-27 differentially inhibits different polymerase activities at the promoter. J Virol 89:7786&#x2013;7798. 10.1128/JVI.00530-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00530-15</ArticleId><ArticleId IdType="pmc">PMC4505683</ArticleId><ArticleId IdType="pubmed">25995255</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman MSA, Liu C, Fung A, Behera I, Jordan P, Rigaux P, Ysebaert N, Tcherniuk S, Sourimant J, El&#xe9;ou&#xeb;t JF, Sutto-Ortiz P, Decroly E, Roymans D, Jin Z, McLellan JS. 2019. Structure of the respiratory syncytial virus polymerase complex. Cell 179:193&#x2013;204.e14. 10.1016/j.cell.2019.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.08.014</ArticleId><ArticleId IdType="pmc">PMC7111336</ArticleId><ArticleId IdType="pubmed">31495574</ArticleId></ArticleIdList></Reference><Reference><Citation>Deval J, Fung A, Stevens SK, Jordan PC, Gromova T, Taylor JS, Hong J, Meng J, Wang G, Dyatkina N, Prhavc M, Symons JA, Beigelman L. 2016. Biochemical effect of resistance mutations against synergistic inhibitors of RSV RNA polymerase. PLoS One 11:e0154097. 10.1371/journal.pone.0154097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0154097</ArticleId><ArticleId IdType="pmc">PMC4862670</ArticleId><ArticleId IdType="pubmed">27163448</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>